Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Intrahepatic Cholangiocarcinoma Recurrent”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05557578
What this trial is testing

GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

Who this might be right for
Intrahepatic Cholangiocarcinoma
Zhejiang Cancer Hospital 20
Testing effectiveness (Phase 2)UnknownNCT04782804
What this trial is testing

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Who this might be right for
Cholangiocarcinoma, Intrahepatic
Fudan University 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04669496
What this trial is testing

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Who this might be right for
Intrahepatic CholangiocarcinomaPD1 AntibodyLenvatinib+1 more
Shanghai Zhongshan Hospital 178
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07243951
What this trial is testing

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Who this might be right for
Combined Hepatocellular-cholangiocarcinomaLiver Neoplasms
Shanghai Zhongshan Hospital 75
Not applicableStudy completedNCT04072250
What this trial is testing

Surgery for Recurrent Intrahepatic Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma, IntrahepaticRecurrence CholangiocarcinomaRe-hepatectomy
Chang Gung Memorial Hospital 216
Large-scale testing (Phase 3)Ended earlyNCT00658593
What this trial is testing

Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Who this might be right for
Extrahepatic Bile Duct CancerGallbladder CancerLiver Cancer
NCIC Clinical Trials Group 19
Testing effectiveness (Phase 2)Looking for participantsNCT06664021
What this trial is testing

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma
Anhui Provincial Hospital 60
Early research (Phase 1)WithdrawnNCT02856568
What this trial is testing

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Who this might be right for
Non-Resectable CholangiocarcinomaRecurrent CholangiocarcinomaStage III Extrahepatic Bile Duct Cancer+10 more
Mayo Clinic
Testing effectiveness (Phase 2)Study completedNCT00005938
What this trial is testing

DX-8951f in Treating Patients With Biliary Cancer

Who this might be right for
Extrahepatic Bile Duct CancerGallbladder CancerLiver Cancer
Daiichi Sankyo
Testing effectiveness (Phase 2)Study completedNCT00553332
What this trial is testing

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Who this might be right for
Liver and Intrahepatic Biliary Tract CancerRecurrent Extrahepatic Bile Duct CancerUnresectable Extrahepatic Bile Duct Cancer
National Cancer Institute (NCI) 29